<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136157</url>
  </required_header>
  <id_info>
    <org_study_id>R 16/2020/2021</org_study_id>
    <nct_id>NCT05136157</nct_id>
  </id_info>
  <brief_title>Intravenous Bolus-infusion Versus Sliding Scale of Insulin for Intra-operative Glycemic Control</brief_title>
  <official_title>Intravenous Bolus-infusion Versus Sliding Scale of Insulin for Intra-operative Glycemic Control in Elective Laparotomy Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-operative blood glucose (BG) concentrations in type 2 diabetic patients undergoing&#xD;
      elective non-cardiac surgery; have an increased incidence of in-hospital morbidity for&#xD;
      cardiopulmonary and infectious complications. Also, hyperglycemia is associated with&#xD;
      increased production and impaired scavenging of oxygen reactive species, polymorph nuclear&#xD;
      neutrophil dysfunction and decreased intracellular killing, resulting in poor wound healing&#xD;
      and increased risk of infection. Thus, perioperative optimal glucose management contributes&#xD;
      to reduced morbidity and mortality. Recommendations favor moderate levels of capillary blood&#xD;
      glucose (CBG); maintaining it in the range of 140-180 mg/dl.&#xD;
&#xD;
      Peri-operative doses of rapidly acting insulin for glycemic control could be done by the&#xD;
      sliding scale or the bolus-infusion approaches. The sliding scale of insulin is commonly used&#xD;
      to manage peri-operative hyper-glycaemia. It involves administering prescribed doses of&#xD;
      insulin when the CBG is within determined ranges and withholding insulin when the CBG is&#xD;
      within normal range. When used as a sole therapy; it results in under-insulinisation and thus&#xD;
      hyper-glycaemia. The use of a dynamic insulin regimen like the intravenous bolus-infusion&#xD;
      approach; allows adjusting the blood glucose level according to the insulin sensitivity of&#xD;
      each patient, thus, better glucose control and less variations than the intermittent&#xD;
      intravenous bolus of short-acting insulin in the sliding scale despite the same blood glucose&#xD;
      target.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      compare the rapidly acting insulin injection via the bolus-infusion approach (Study group) to&#xD;
      the sliding scale approach (Control group) as regards the intra-operative glycemic control&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intra-operative CBG level between 140- 180 mg/dl all over the operation</measure>
    <time_frame>7 months</time_frame>
    <description>Base line CBG will be measured for all patients then every 30 minutes and in the PACU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total IU of rapidly acting insulin given to the patient</measure>
    <time_frame>7 months</time_frame>
    <description>total units of insulin given to the patient will be calculated in the PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-operative changes in serum potassium</measure>
    <time_frame>7 months</time_frame>
    <description>Base line serum potassium will be compared to that measured in the PACU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Intraoperative Complications</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus-Infusion approach of rapidly acting crystalline insulin. The patient intra-operative blood glucose will be divided by 100. The resultant rapidly acting crystalline insulin units will be given intravenously over 10 minutes, and then continued as an intra-venous infusion per hour. The Capillary Blood Glucose (CBG) will be measured every 30 minutes and in the PACU with readjustment of the bolus-infusion dose as required</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The sliding scale approach of rapidly acting crystalline insulin will be used according to the intra-operative blood glucose; 4 IU of insulin will be given when the CBG 180-250 mg/dl, 6 IU of insulin will be given when the CBG 251-300 mg/dl, 8 IU of insulin will be given when the CBG 301-350 mg/dl and 10 IU of insulin will be given when the CBG 351-400 mg/dl (5). The CBG will be measured every 30 minutes and in the PACU.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapid-Acting Insulin</intervention_name>
    <description>50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Crystalline insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA physical status II patients&#xD;
&#xD;
          -  aged 21-65 years&#xD;
&#xD;
          -  known to have type1 or 2 diabetes mellitusw&#xD;
&#xD;
          -  pre-operative fasting blood glucose level ˂ 350 mg/dl&#xD;
&#xD;
          -  scheduled to undergo elective laparotomy surgeries&#xD;
&#xD;
          -  expected to exceed 2 hours duration under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients' refusal&#xD;
&#xD;
          -  diabetic ketoacidosis&#xD;
&#xD;
          -  hyperglycemic hyperosmolar syndrome&#xD;
&#xD;
          -  serum potassium ˂3.5 mEq/L&#xD;
&#xD;
          -  HbA1c &gt;8.5%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ghada M.Samir</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesia, Intensive care and Pain Management</investigator_title>
  </responsible_party>
  <keyword>Insulin</keyword>
  <keyword>Intra operative</keyword>
  <keyword>Sliding scale</keyword>
  <keyword>Bolus- infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intraoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

